Japan Medical Dynamic Marketing: Announcements of individual stocks regarding the start of sales of new commodity etf JMDM BIOCERAM AZUL ceramic head.
Japan Medical Dynamic Marketing: Overview of consolidated financial performance for the first quarter of the fiscal year ending in March 2025 [Japan GAAP]
Japan Medical Dynamic Marketing: Announcements of individual stocks regarding the acquisition of drug approval for the new product Ovation Tribute NEO stem for artificial joint.
Japan Medical Dynamic Marketing: Announcements of individual stocks for the MSCI ESG ETFs, "FTSE Blossom Japan Sector Relative Index", in terms of constituent selection.
Japan Medical Dynamic Marketing: Regarding matters related to dominant shareholders.
Japan Medical Dynamic Marketing: Notice regarding the formulation of the “Long-Term VISION RT500, 1st Stage Management Plan”
Japan Medical Dynamic Marketing: Overview of consolidated financial results for the fiscal year ended 2024/3 [Japanese GAAP]
Japan Medical Dynamic Marketing: Notice regarding personnel affairs of executive officers
Japan Medical Dynamic Marketing: Notice regarding personnel affairs of directors and auditors
Japan Medical Dynamic Marketing: Notice regarding US Food and Drug Administration (FDA) regulatory approval and US sales of the new hip prosthetic product Trivicta Hip Stem
Mdm Japan: Notice regarding obtaining regulatory approval for the “Balanced Knee System” manufactured in China and commencement of sales in the Chinese market
Japan Medical Dynamic Marketing: Notice regarding sales of the new knee prosthetic product “Balanced Knee System Uni” in Japan
Japan Medical Dynamic Marketing: Summary of Financial Results for the Third Quarter of the Fiscal Year Ending March 2024[Japanese GAAP]
Japan Medical Dynamic Marketing: Notice regarding the introduction of a new surgical support robot system manufactured by THINK Surgical Inc.
Japan Medical Dynamic Marketing: Notice regarding personnel changes
Japan Medical Dynamic Marketing: Summary of Financial Results for the Second Quarter of the Fiscal Year Ending March 2024[Japanese GAAP]
Japan Medical Dynamic Marketing: Entered the regenerative medicine field (knee joint) and began selling the knee joint early treatment product PRP-FD to medical facilities
Japan Medical Dynamic Marketing: Summary of Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 2024 [Japanese GAAP]
Japan Medical Dynamic Marketing: Matters relating to controlling shareholders, etc.
Japan Medical Dynamic Marketing: Notice regarding personnel changes
No Data